Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ponatinib
Drug ID BADD_D01799
Description Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Indications and Usage Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
Marketing Status Prescription
ATC Code L01EA05
DrugBank ID DB08901
KEGG ID D09950
MeSH ID C545373
PubChem ID 24826799
TTD Drug ID D0H0EQ
NDC Product Code Not Available
Synonyms ponatinib | 3-(2-(imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide | ponatinib hydrochloride | AP24534 | AP-24534 | AP 24534 | Iclusig
Chemical Information
Molecular Formula C29H27F3N6O
CAS Registry Number 943319-70-8
SMILES CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Arterial occlusive disease24.04.02.0210.000799%Not Available
Effusion08.01.03.052--Not Available
Cerebral artery stenosis24.04.06.023; 17.08.02.010--Not Available
Blood count abnormal13.01.07.0010.003197%Not Available
Exfoliative rash23.03.07.006--Not Available
Pulmonary arterial hypertension22.06.01.002; 24.08.03.0030.000208%Not Available
Bone marrow failure01.03.03.0050.001332%
Cardiovascular insufficiency24.06.03.005; 02.01.01.0110.000139%Not Available
Cytopenia01.03.03.0120.001865%Not Available
Treatment failure08.06.01.017--Not Available
Liver injury12.01.02.003; 09.01.07.0220.001332%Not Available
Acute kidney injury20.01.03.0160.002398%
Posterior reversible encephalopathy syndrome17.13.02.0070.001332%
Central nervous system haemorrhage17.08.01.035; 24.07.04.0160.000139%Not Available
Peripheral artery stenosis24.04.03.0170.000799%Not Available
Peripheral artery thrombosis24.01.02.0100.000533%Not Available
Aspergillus infection11.03.01.0040.000208%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000486%
Liver function test increased13.03.01.0440.000799%Not Available
Full blood count decreased13.01.07.0040.001066%Not Available
Philadelphia chromosome positive13.22.02.0030.000533%Not Available
Pneumonia influenzal22.07.05.008; 11.05.03.0030.000139%Not Available
Terminal state08.01.03.0790.000533%Not Available
Blast crisis in myelogenous leukaemia16.01.08.002; 01.10.08.0020.000695%Not Available
Clostridium difficile infection11.02.02.0090.000799%Not Available
Secondary immunodeficiency10.03.03.0090.000533%Not Available
Klebsiella infection11.02.03.0030.000533%Not Available
Leukaemia recurrent16.01.03.005; 01.10.03.0050.000486%Not Available
Acute lymphocytic leukaemia recurrent16.01.01.003; 01.10.01.0030.001251%Not Available
Graft versus host disease in skin23.07.04.025; 12.02.09.031; 10.02.01.0620.001066%Not Available
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages